|

Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy Clinical Trials

1 actively recruiting trial

Also known as: Dalpiciclib/AI combination therapy, SHR6390 + aromatase inhibitor

Pipeline

Phase 2: 1

Top Sponsors

  • Peking University People's Hospital1

Indications

  • ctDNA Monitoring1
  • High-risk Breast Cancer1
  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)1
  • HER2-negative Breast Cancer1
  • Hormone Receptor Positive Breast Cancer1

Other1 trial

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.